Advertisement

Rheumatology International

, Volume 39, Issue 3, pp 541–549 | Cite as

Secular trends in the incidence and prevalence of rheumatoid arthritis within members of an integrated health care delivery system

  • Aniket A. KawatkarEmail author
  • Sherine E. Gabriel
  • Steven J. Jacobsen
Public Health
  • 28 Downloads

Abstract

The study objective was to estimate secular trends in the overall incidence rate (IR) and prevalence rate (PR) of rheumatoid arthritis (RA); and subgroup-specific IR and PR by race, ethnicity, and sex in a multi-ethnic population of a large integrated health care delivery system. An ecological study was conducted within the adult population of Kaiser Permanente Southern California health plan. From January 1995 up to and including December 2014, annual IR and PR were calculated separately by race, ethnicity, sex and pooled overall. Depending on the stationarity of each ecological series, annual percentage change in IR and PR was evaluated using auto-regressive integrated moving average models. Average overall IR was 53 [95% confidence interval (CI) 46, 61] per 100,000 person-years. The overall as well as subgroup-specific annual IR of RA were unchanged from 1995 to 2014. In 1995, the overall PR of RA was 59 (44, 74) per 100,000 person-years which increased by 14% (7%, 21%) annually thereafter. The increase in PR in Caucasians was lower as compared to African American, Asian and other race (13% vs 15%, 15%, and 18%, respectively). Compared to non-Hispanic ethnicity, the increase in PR among Hispanic was higher (17% vs 14%). Over the past 2 decades, while the incidence of RA was unchanged, the prevalence had increased significantly overall as well as within every subgroup of race, ethnicity, and sex.

Keywords

Rheumatoid arthritis Incidence Prevalence Secular trends Box–Jenkins models 

Notes

Funding

There was no funding received for this study.

Compliance with ethical standards

Conflict of interest

Aniket A. Kawatkar, Sherine E. Gabriel, and Steven J. Jacobsen have no direct conflict of interests. Dr. Kawatkar reports grants from Medac Pharma, grants from Bristol-Myers Squibb, outside the submitted work.

Ethical approval

The study was approved by the Kaiser Permanente Southern California Institutional Review Board.

Supplementary material

296_2018_4235_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 19 KB)
296_2018_4235_MOESM2_ESM.docx (20 kb)
Supplementary material 2 (DOCX 19 KB)
296_2018_4235_MOESM3_ESM.docx (16 kb)
Supplementary material 3 (DOCX 15 KB)
296_2018_4235_MOESM4_ESM.docx (16 kb)
Supplementary material 4 (DOCX 16 KB)

References

  1. 1.
    Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58(1):15–25CrossRefGoogle Scholar
  2. 2.
    Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising? Results from Olmsted County. Arthritis Rheum 62(6):1576–82 (Minnesota, 1955–2007) CrossRefGoogle Scholar
  3. 3.
    Jean S, Hudson M, Gamache P et al (2017) Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study. Clin RheumatolGoogle Scholar
  4. 4.
    Dadoun S, Zeboulon-Ktorza N, Combescure C et al (2013) Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint, bone, spine: revue du rhumatisme 80(1):29–33CrossRefGoogle Scholar
  5. 5.
    Koebnick C, Langer-Gould AM, Gould MK et al (2012) Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Permanente J 16(3):37–41CrossRefGoogle Scholar
  6. 6.
    Granger CWJ, Newbold P (1974) Spurious regressions in econometrics. J Econ 2:111–120CrossRefGoogle Scholar
  7. 7.
    Phillips PCB (1986) Understanding spurious regressions in econometrics. J Econ 33:311–340CrossRefGoogle Scholar
  8. 8.
    Box GEP, Jenkins GM (1970) Time series analysis: forecasting and control. Holden-Day, San FranciscoGoogle Scholar
  9. 9.
    Akushevich I, Kravchenko J, Ukraintseva S, Arbeev K, Yashin AI (2013) Time trends of incidence of age-associated diseases in the US elderly population: medicare-based analysis. Age Ageing 42(4):494–500CrossRefGoogle Scholar
  10. 10.
    Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA (2016) Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation Among US adults, 2015–2040. Arthritis Rheumatol 68(7):1582–1587CrossRefGoogle Scholar
  11. 11.
    Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM (2013) Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 65(2):334–342CrossRefGoogle Scholar
  12. 12.
    Ajeganova S, Andersson ML, Frostegard J, Hafstrom I (2013) Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J RheumatolGoogle Scholar
  13. 13.
    Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Therapy 11(3):229CrossRefGoogle Scholar
  14. 14.
    Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732CrossRefGoogle Scholar
  15. 15.
    Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB (2013) Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res 65(2):299–303CrossRefGoogle Scholar
  16. 16.
    Kawatkar AA, Hay JW, Stohl W, Nichol MB (2013) Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ 22(7):807–823CrossRefGoogle Scholar
  17. 17.
    Ezzati M, Riboli E (2013) Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med 369(10):954–964CrossRefGoogle Scholar
  18. 18.
    Demoruelle MK, Deane KD (2012) Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep 14(5):472–480CrossRefGoogle Scholar
  19. 19.
    Wevers-de Boer KV, Heimans L, Huizinga TW, Allaart CF (2013) Drug therapy in undifferentiated arthritis: a systematic literature review. Ann Rheum Dis 72(9):1436–1444CrossRefGoogle Scholar
  20. 20.
    Alamanos Y, Voulgari PV, Drosos AA (2006) Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36(3):182–188CrossRefGoogle Scholar
  21. 21.
    Costenbader KH, Chang SC, Laden F, Puett R, Karlson EW (2008) Geographic variation in rheumatoid arthritis incidence among women in the United States. Arch Intern Med 168(15):1664–1670CrossRefGoogle Scholar
  22. 22.
    Kaipiainen-Seppanen O, Kautiainen H (2006) Declining trend in the incidence of rheumatoid factor-positive rheumatoid arthritis in Finland 1980–2000. J Rheumatol 33(11):2132–2138Google Scholar
  23. 23.
    Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K (2009) Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int 29(4):411–415CrossRefGoogle Scholar
  24. 24.
    Pedersen JK, Svendsen AJ, Horslev-Petersen K (2007) Incidence of Rheumatoid Arthritis in the southern part of Denmark from 1995 to 2001. Open Rheumatol J 1:18–23CrossRefGoogle Scholar
  25. 25.
    Rodriguez LA, Tolosa LB, Ruigomez A, Johansson S, Wallander MA (2009) Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 38(3):173–177CrossRefGoogle Scholar
  26. 26.
    MacGregor AJ, Silman AJ (1992) A reappraisal of the measurement of disease occurrence in rheumatoid arthritis. J Rheumatol 19(8):1163–1165Google Scholar
  27. 27.
    Minichiello E, Semerano L, Boissier MC (2016) Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: a systematic literature review. Joint, Bone, Spine: revue du rhumatisme 83(6):625–630CrossRefGoogle Scholar
  28. 28.
    Englund M, Joud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF (2010) Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology 49(8):1563–1569CrossRefGoogle Scholar
  29. 29.
    Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J (2013) Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res 65(6):870–878CrossRefGoogle Scholar
  30. 30.
    Odegard S, Kvien TK, Uhlig T (2008) Incidence of clinically important 10-year health status and disease activity levels in population-based cohorts with rheumatoid arthritis. J Rheumatol 35(1):54–60Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Research and EvaluationKaiser Permanente Southern CaliforniaPasadenaUSA
  2. 2.Rutgers Robert Wood Johnson Medical SchoolNew BrunswickUSA
  3. 3.Division of Rheumatology, Department of Health Sciences ResearchMayo Clinic College of MedicineRochesterUSA

Personalised recommendations